Seminars in Nuclear Medicine
Volume 40, Issue 4 , Pages 294-315 , July 2010

Physiology and Pathophysiology of Incidental Findings Detected on FDG-PET Scintigraphy

References 

  1. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: A hardware approach to image fusion. Semin Nucl Med. 2003;33:193–204
  2. Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400–419
  3. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508
  4. Federman N, Feig SA. PET/CT in evaluating pediatric malignancies: A clinician's perspective. J Nucl Med. 2007;48:1920–1922
  5. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–332
  6. Kapoor V, Mccook BM, Torok FS. An introduction to PET-CT imaging. Radiographics. 2004;24:523–543
  7. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001;39:883–917
  8. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811–1817
  9. Bos R, Van Der Hoeven JJ, van der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–387
  10. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9–16
  11. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–530
  12. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447–5454
  13. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551–578
  14. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50:11S–20S(suppl 1)
  15. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355–359
  16. Wahl RL, Henry CA, Ethier SP. Serum glucose: Effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d[r]-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643–647
  17. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer—A PET study. J Nucl Med. 1993;34:1–6
  18. Turcotte E, Leblanc M, Carpentier A, et al. Optimization of whole-body positron emission tomography imaging by using delayed 2-deoxy-2-[F-18]fluoro-D-glucose injection following IV insulin in diabetic patients. Mol Imaging Biol. 2006;8:348–354
  19. Chin BB, Green ED, Turkington TG, et al. Increasing uptake time in FDG-PET: Standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol. 2009;11:118–122
  20. Sanz-Viedma S, Torigian DA, Parsons M, et al. Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: Implications for oncological imaging. Rev Esp Med Nucl. 2009;28:159–166
  21. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification?. J Nucl Med. 1994;35:1308–1312
  22. Lowe VJ, Delong DM, Hoffman JM, et al. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995;36:883–887
  23. Prabhakar HB, Sahani DV, Fischman AJ, et al. Bowel hot spots at PET-CT. Radiographics. 2007;27:145–159
  24. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med. 2004;45:82S–95S(suppl 1)
  25. Nakamoto Y, Chin BB, Kraitchman DL, et al. Effects of nonionic intravenous contrast agents at PET/CT imaging: Phantom and canine studies. Radiology. 2003;227:817–824
  26. Goerres GW, Ziegler SI, Burger C, et al. Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology. 2003;226:577–584
  27. Keyes JW. SUV: Standard uptake or silly useless value?. J Nucl Med. 1995;36:1836–1839
  28. Bar-Shalom R. Muscle uptake of 18-fluorine fluorodeoxyglucose. Semin Nucl Med. 2000;30:306–309
  29. El-Haddad G, Alavi A, Mavi A, et al. Normal variants in [18F]-fluorodeoxyglucose PET imaging. Radiol Clin North Am 42:1063-1081, viii; 2004;
  30. American College of Radiology: COQaS: ACR Practice Guideline for Performing FDG-PET/CT in Oncology 2007, 2007, Amended 2009
  31. Alavi A, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32:293–321
  32. Nakahara T, Fujii H, Ide M, et al. FDG uptake in the morphologically normal thymus: Comparison of FDG positron emission tomography and CT. Br J Radiol. 2001;74:821–824
  33. Patel PM, Alibazoglu H, Ali A, et al. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med. 1996;21:772–775
  34. Vranjesevic D, Schiepers C, Silverman DH, et al. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med. 2003;44:1238–1242
  35. Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol. 2000;126:560–574
  36. Hicks RJ, Binns D, Stabin MG. Pattern of uptake and excretion of (18)F-FDG in the lactating breast. J Nucl Med. 2001;42:1238–1242
  37. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409–1415
  38. Koga H, Sasaki M, Kuwabara Y, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med. 2003;17:733–738
  39. Rosenbaum SJ, Lind T, Antoch G, et al. False-positive FDG PET uptake—The role of PET/CT. Eur Radiol. 2006;16:1054–1065
  40. Tatlidil R, Jadvar H, Bading JR, et al. Incidental colonic fluorodeoxyglucose uptake: Correlation with colonoscopic and histopathologic findings. Radiology. 2002;224:783–787
  41. Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med. 2001;42:989–992
  42. Zhuang H, Hickeson M, Chacko TK, et al. Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin Nucl Med. 2002;27:628–632
  43. Liu Y. Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl Med Commun. 2009;30:763–769
  44. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics. 1999;19:61–77quiz:150-151
  45. Kamel EM, Jichlinski P, Prior JO, et al. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med. 2006;47:1803–1807
  46. Liu Y. Benign ovarian and endometrial uptake on FDG PET-CT: Patterns and pitfalls. Ann Nucl Med. 2009;23:107–112
  47. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: Assessment by PET/CT. J Nucl Med. 2004;45:266–271
  48. Chander S, Meltzer CC, Mccook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med. 2002;27:22–24
  49. Nishizawa S, Inubushi M, Okada H. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging. 2005;32:549–556
  50. Kosuda S, Fisher S, Kison PV, et al. Uptake of 2-deoxy-2-[18F]fluoro-d[r]-glucose in the normal testis: Retrospective PET study and animal experiment. Ann Nucl Med. 1997;11:195–199
  51. Yeung HW, Grewal RK, Gonen M, et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: A potential source of false-positives for PET. J Nucl Med. 2003;44:1789–1796
  52. Reinking MF, Osman MM. Prospective evaluation of physiologic uptake detected with true whole-body 18F-FDG PET/CT in healthy subjects. J Nucl Med Technol. 2009;37:31–37
  53. Hany TF, Gharehpapagh E, Kamel EM, et al. Brown adipose tissue: A factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002;29:1393–1398
  54. Garcia CA, Van Nostrand D, Atkins F, et al. Reduction of brown fat 2-deoxy-2-[F-18]fluoro-d[r]-glucose uptake by controlling environmental temperature prior to positron emission tomography scan. Mol Imaging Biol. 2006;8:24–29
  55. Cohade C, Mourtzikos KA, Wahl RL. “US-Fat”: Prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med. 2003;44:1267–1270
  56. Paidisetty S, Blodgett TM. Brown fat: Atypical locations and appearances encountered in PET/CT. AJR Am J Roentgenol. 2009;193:359–366
  57. Agress H, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: Histopathologic comparison. Radiology. 2004;230:417–422
  58. Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: Incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46:758–762
  59. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med. 2005;46:752–757
  60. Even-Sapir E, Lerman H, Gutman M, et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging. 2006;33:541–552
  61. Beatty JS, Williams HT, Aldridge BA, et al. Incidental PET/CT findings in the cancer patient: How should they be managed?. Surgery. 2009;146:274–281
  62. Ozkol V, Alper E, Aydin N, et al. The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography. Nucl Med Commun. 2010;31:128–136
  63. Hosaka Y, Tawata M, Kurihara A, et al. The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropin. Endocrinology. 1992;131:159–165
  64. Karantanis D, Bogsrud TV, Wiseman GA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med. 2007;48:896–901
  65. Liu Y. Clinical significance of thyroid uptake on F 18-fluorodeoxyglucose positron emission tomography. Ann Nucl Med. 2009;23:17–23
  66. Chen YK, Chen YL, Cheng RH, et al. The significance of FDG uptake in bilateral thyroid glands. Nucl Med Commun. 2007;28:117–122
  67. Kurata S, Ishibashi M, Hiromatsu Y, et al. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: Prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med. 2007;21:325–330
  68. Chen YK, Wang YF, Chiu JS. Diagnostic trinity: Graves' disease on F-18 FDG PET. Clin Nucl Med. 2007;32:816–817
  69. Burguera B, Gharib H. Thyroid incidentalomas (Prevalence, diagnosis, significance, and management). Endocrinol Metab Clin North Am. 2000;29:187–203
  70. Choi JY, Lee KS, Kim HJ, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: Clinical significance and improved characterization. J Nucl Med. 2006;47:609–615
  71. Bogsrud TV, Karantanis D, Nathan MA, et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun. 2007;28:373–381
  72. Kamel EM, Goerres GW, Burger C, et al. Recurrent laryngeal nerve palsy in patients with lung cancer: Detection with PET-CT image fusion—Report of six cases. Radiology. 2002;224:153–156
  73. Kostakoglu L, Wong JC, Barrington SF, et al. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med. 1996;37:1771–1773
  74. Lee M, Ramaswamy MR, Lilien DL, et al. Unilateral vocal cord paralysis causes contralateral false-positive positron emission tomography scans of the larynx. Ann Otol Rhinol Laryngol. 2005;114:202–206
  75. Davis E, Solis V, Rosenberg RJ, et al. Asymmetric tongue muscle uptake of F-18 FDG: Possible marker for cranial nerve XII paralysis. Clin Nucl Med. 2004;29:531–533
  76. Korn RL, Yost AM, May CC, et al. Unexpected focal hypermetabolic activity in the breast: Significance in patients undergoing 18F-FDG PET/CT. AJR Am J Roentgenol. 2006;187:81–85
  77. Litmanovich D, Gourevich K, Israel O, et al. Unexpected foci of 18F-FDG uptake in the breast detected by PET/CT: Incidence and clinical significance. Eur J Nucl Med Mol Imaging. 2009;36:1558–1564
  78. Beatty JS, Williams HT, Gucwa AL, et al. The predictive value of incidental PET/CT findings suspicious for breast cancer in women with non-breast malignancies. Am J Surg. 2009;198:495–499
  79. Gil-Rendo A, Martinez-Regueira F, Zornoza G, et al. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166–170
  80. Jerushalmi J, Frenkel A, Bar-Shalom R, et al. Physiologic thymic uptake of 18F-FDG in children and young adults: A PET/CT evaluation of incidence, patterns, and relationship to treatment. J Nucl Med. 2009;50:849–853
  81. Brink I, Reinhardt MJ, Hoegerle S, et al. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: Age dependency and frequency after chemotherapy. J Nucl Med. 2001;42:591–595
  82. Smith CS, Schoder H, Yeung HW. Thymic extension in the superior mediastinum in patients with thymic hyperplasia: Potential cause of false-positive findings on 18F-FDG PET/CT. AJR Am J Roentgenol. 2007;188:1716–1721
  83. Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics. 2004;24:1611–1616
  84. Wittram C, Fischman AJ, Mark E, et al. Thymic enlargement and FDG uptake in three patients: CT and FDG positron emission tomography correlated with pathology. AJR Am J Roentgenol. 2003;180:519–522
  85. Sasaki M, Kuwabara Y, Ichiya Y, et al. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J Nucl Med. 1999;40:1595–1601
  86. Ramos CD, Erdi YE, Gonen M, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med. 2001;28:155–164
  87. Inoue K, Goto R, Okada K, et al. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Ann Nucl Med. 2009;23:643–649
  88. Kazama T, Swanston N, Podoloff DA, et al. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406–1411
  89. Yao WJ, Hoh CK, Hawkins RA, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36:794–799
  90. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773–1778
  91. Inoue K, Okada K, Harigae H, et al. Diffuse bone marrow uptake on F-18 FDG PET in patients with myelodysplastic syndromes. Clin Nucl Med. 2006;31:721–723
  92. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 1999;40:1407–1413
  93. Liu SH, Chang JT, Ng SH, et al. False positive fluorine-18 fluorodeoxy-d[r]-glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. Br J Radiol. 2004;77:257–260
  94. Sohn MH, Jeong HJ, Lim ST, et al. F-18 FDG uptake in osteonecrosis mimicking bone metastasis on PET/CT images. Clin Nucl Med. 2007;32:496–497
  95. Demir H, Halac M, Gorur GD, et al. FDG PET/CT findings in primary hyperparathyroidism mimicking multiple bone metastases. Eur J Nucl Med Mol Imaging. 2008;35:686
  96. Lin P, Delaney G, Chu J, et al. Fluorine-18 FDG dual-head gamma camera coincidence imaging of radiation pneumonitis. Clin Nucl Med. 2000;25:866–869
  97. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. J Am Med Assoc. 2001;285:914–924
  98. Osman MM, Cohade C, Nakamoto Y, et al. Clinically significant inaccurate localization of lesions with PET/CT: Frequency in 300 patients. J Nucl Med. 2003;44:240–243
  99. Hany TF, Heuberger J, von Schulthess GK. Iatrogenic FDG foci in the lungs: A pitfall of PET image interpretation. Eur Radiol. 2003;13:2122–2127
  100. Farsad M, Ambrosini V, Nanni C, et al. Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. Nucl Med Commun. 2005;26:827–830
  101. Karantanis D, Subramaniam RM, Mullan BP, et al. Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. J Comput Assist Tomogr. 2007;31:800–805
  102. Ha JM, Jeong SY, Seo YS, et al. Incidental focal F-18 FDG accumulation in lung parenchyma without abnormal CT findings. Ann Nucl Med. 2009;23:599–603
  103. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–1998
  104. Yen RF, Chen YC, Wu YW, et al. Using 18-fluoro-2-deoxyglucose positron emission tomography in detecting infectious endocarditis/endoarteritis: A preliminary report. Acad Radiol. 2004;11:316–321
  105. Jingu K, Kaneta T, Nemoto K, et al. The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. Int J Radiat Oncol Biol Phys. 2006;66:845–851
  106. Khandani AH, Isasi CR, Blaufox MD. Intra-individual variability of cardiac uptake on serial whole-body 18F-FDG PET. Nucl Med Commun. 2005;26:787–791
  107. Kaneta T, Hakamatsuka T, Takanami K, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med. 2006;20:203–208
  108. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis. 1972;15:289–329
  109. De Groot M, Meeuwis AP, Kok PJ, et al. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32:98–101
  110. Su HY, Huang HL, Sun CM, et al. Primary cardiac lymphoma evaluated with integration of PET/CT and contrast-enhanced CT. Clin Nucl Med. 2009;34:298–301
  111. Moulin-Romsee G, De Wever W, Verbeken E, et al. Atrial metastasis of esophageal carcinoma detected by follow-up FDG PET/CT. Clin Nucl Med. 2007;32:393–395
  112. Orcurto MV, Delaloye AB, Letovanec I, et al. Detection of an asymptomatic right-ventricle cardiac metastasis from a small-cell lung cancer by F-18-FDG PET/CT. J Thorac Oncol. 2009;4:127–130
  113. Bhargava P, Reich P, Alavi A, et al. Radiation-induced esophagitis on FDG PET imaging. Clin Nucl Med. 2003;28:849–850
  114. Kamel EM, Thumshirn M, Truninger K, et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: Correlation with endoscopic and histopathologic results. J Nucl Med. 2004;45:1804–1810
  115. Ba-Ssalamah A, Zacherl J, Noebauer-Huhmann IM, et al. Dedicated multi-detector CT of the esophagus: Spectrum of diseases. Abdom Imaging. 2009;34:3–18
  116. Blake MA, Singh A, Setty BN, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics. 2006;26:1335–1353
  117. Cook DM, Loriaux DL. The incidental adrenal mass. Am J Med. 1996;101:88–94
  118. Jana S, Zhang T, Milstein DM, et al. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging. 2006;33:29–35
  119. Welch TJ, Sheedy PF, Stephens DH, et al. Percutaneous adrenal biopsy: Review of a 10-year experience. Radiology. 1994;193:341–344
  120. Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42:1795–1799
  121. Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004;45:2058–2062
  122. Elaini AB, Shetty SK, Chapman VM, et al. Improved detection and characterization of adrenal disease with PET-CT. Radiographics. 2007;27:755–767
  123. Chong S, Lee KS, Kim HY, et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: Diagnostic efficacy and interpretation pitfalls. Radiographics. 2006;26:1811–1824discussion:1824-1816
  124. Coll DM, Smith RC. Update on radiological imaging of renal cell carcinoma. BJU Int. 2007;99:1217–1222
  125. Kang DE, White RL, Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–1809
  126. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–292
  127. Bural GG, Mavi A, Kumar R, et al. FDG uptake in intercostal muscles is an indicator of severe respiratory disease. Clin Nucl Med. 2004;29:807–808
  128. Matthews R, Franceschi D, Cabahug C. Abdominal muscle uptake on FDG PET secondary to multiple rib fractures and use of accessory muscles of respiration. Clin Nucl Med. 2005;30:333–334
  129. Lin FI, Foster CC, Hagge RJ, et al. Extensive FDG uptake in accessory muscles of respiration in a patient with shortness of breath. Clin Nucl Med. 2009;34:428–430
  130. Sakamoto A, Jono O, Hirahashi M, et al. Epithelioid sarcoma with muscle metastasis detected by positron emission tomography. World J Surg Oncol. 2008;6:84
  131. Liu Y, Ghesani N, Mirani N, et al. PET-CT demonstration of extensive muscle metastases from breast cancer. Clin Nucl Med. 2006;31:266–268
  132. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–1980
  133. Paik JY, Lee KH, Choe YS, et al. Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med. 2004;45:124–128
  134. Izquierdo-Garcia D, Davies JR, Graves MJ, et al. Comparison of methods for magnetic resonance-guided [18-F]fluorodeoxyglucose positron emission tomography in human carotid arteries: Reproducibility, partial volume correction, and correlation between methods. Stroke. 2009;40:86–93
  135. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695
  136. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871–878
  137. Tahara N, Imaizumi T, Virmani R, et al. Clinical feasibility of molecular imaging of plaque inflammation in atherosclerosis. J Nucl Med. 2009;50:331–334
  138. Ben-Haim S, Kupzov E, Tamir A, et al. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med. 2004;45:1816–1821
  139. Bural GG, Torigian DA, Chamroonrat W, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008;35:562–569
  140. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008;15:209–217
  141. Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611–1620
  142. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  143. Goerres GW, von Schulthess GK, Hany TF. Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR Am J Roentgenol. 2002;179:1337–1343
  144. Kim EE, Chung SK, Haynie TP, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics. 1992;12:269–279
  145. Nakayama Y, Makino S, Fukuda Y, et al. Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1996;34:459–467
  146. Shon IH, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nucl Med. 2002;32:240–271
  147. Basu S, Alavi A. Defining co-related parameters between “metabolic” flare and “clinical,” “biochemical,” and “osteoblastic” flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging. 2007;34:441–443
  148. James SL, Davies AM. Post-operative imaging of soft tissue sarcomas. Cancer Imaging. 2008;8:8–18
  149. Bruzzi JF, Truong MT, Marom EM, et al. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol. 2006;187:1116–1123
  150. Osman MM, Cohade C, Fishman EK, et al. Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: Frequency in 250 patients. J Nucl Med. 2005;46:1352–1355
  151. Liu Y. Metastatic brain lesions may demonstrate photopenia on FDG-PET. Clin Nucl Med. 2008;33:255–257
  152. Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155:994–998
  153. Castellsague X, Quintana MJ, Martinez MC, et al. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer. 2004;108:741–749
  154. Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-96. Int J Cancer. 2001;93:155–161
  155. Ueno M, Muto T, Oya M, et al. Multiple primary cancer: An experience at the Cancer Institute hospital with special reference to colorectal cancer. Int J Clin Oncol. 2003;8:162–167
  156. Wang G, Lau EW, Shakher R, et al. How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?. Cancer. 2007;109:117–124
  157. Basu S, Houseni M, Alavi A. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management. Nucl Med Commun. 2008;29:367–373

PII: S0001-2998(10)00013-9

doi: 10.1053/j.semnuclmed.2010.02.002

Seminars in Nuclear Medicine
Volume 40, Issue 4 , Pages 294-315 , July 2010

Article Tools

* Image Usage & Resolution